CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
LY3022855 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03101254
NCT03101254Phase 2Completed
CompareCT.gov

A Phase I/II Study of LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Dana-Farber Cancer Institute·interventional·Posted Apr 5, 2017·Updated Jul 17, 2024

In Brief

A Phase 2 clinical trial evaluating LY3022855, Vemurafenib, and 1 other intervention for Melanoma. Completed, enrolled 5 participants across 1 site.

Detailed Summary

This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation The interventions involved in this study are: * LY3022855 * Vemurafenib * Cobimetinib

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
CollaboratorsEli Lilly and Company

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 5, 2017
Enrollment StartJun 6, 2017
Primary CompletionOct 21, 2020
Study CompletionNov 11, 2020
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 9.2 years ago

Interventions

LY3022855drug

LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor

Vemurafenibdrug

Vemurafenib is a BRAF inhibitor that works by blocking altered BRAF proteins from stimulating the growth of melanoma cancer cells

Cobimetinibdrug

Cobimetinib works by blocking a protein called MEK that has been known to promote melanoma growth